These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8616707)

  • 21. Rapid intravenous infusion of velaglucerase-alfa in adults with type 1 Gaucher disease.
    Zimran A; Revel-Vilk S; Becker-Cohen M; Chicco G; Arbel N; Rolfs A; Szer J
    Am J Hematol; 2018 Sep; 93(9):E246-E248. PubMed ID: 29989200
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Gaucher's disease.
    Moscicki RA; Taunton-Rigby A
    N Engl J Med; 1993 May; 328(21):1564; author reply 1567-8. PubMed ID: 8373459
    [No Abstract]   [Full Text] [Related]  

  • 23. In brief: Taliglucerase (Elelyso) for Gaucher disease.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):56. PubMed ID: 22966489
    [No Abstract]   [Full Text] [Related]  

  • 24. Ceredase dosing concerns for Gaucher's disease.
    Moscicki RA; van Heek J
    Am J Med; 1994 Oct; 97(4):402-3. PubMed ID: 7942949
    [No Abstract]   [Full Text] [Related]  

  • 25. Gaucher's treatment: first things first.
    Turpen TH
    Nat Med; 1996 Sep; 2(9):950. PubMed ID: 8782441
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of enzyme therapy in a patient with Gaucher disease type III.
    Bosman DK; Hollak CE; Aerts JM; Bakker HD
    J Inherit Metab Dis; 1996; 19(5):703-4. PubMed ID: 8892032
    [No Abstract]   [Full Text] [Related]  

  • 27. [Enzyme therapy of Gaucher's disease].
    Beck M
    Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Gaucher's disease.
    Hollak CE; Aerts JM; van Oers MH
    N Engl J Med; 1993 May; 328(21):1565-6; author reply 1567. PubMed ID: 8479498
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of Gaucher's disease.
    Barton NW; Brady RO; Dambrosia JM
    N Engl J Med; 1993 May; 328(21):1564-5; author reply 1567-8. PubMed ID: 8479496
    [No Abstract]   [Full Text] [Related]  

  • 30. Enzyme-replacement therapy for Gaucher's disease.
    N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.
    Czartoryska B; Tylki-Szymańska A; Lugowska A
    Clin Biochem; 2000 Mar; 33(2):147-9. PubMed ID: 10751594
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic malpractice in the treatment of Gaucher's disease.
    Beutler E
    Am J Med; 1994 Jul; 97(1):1-2. PubMed ID: 8030649
    [No Abstract]   [Full Text] [Related]  

  • 33. Pulmonary hypertension in Gaucher's disease.
    Pastores GM; Miller A
    Lancet; 1998 Aug; 352(9127):580. PubMed ID: 9716094
    [No Abstract]   [Full Text] [Related]  

  • 34. Short-term withdrawal from imiglucerase: what can we learn from it?
    Hollak CE
    Blood Cells Mol Dis; 2011 Jan; 46(1):105-6. PubMed ID: 20684887
    [No Abstract]   [Full Text] [Related]  

  • 35. Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
    Migita M; Hamada H; Fujimura J; Watanabe A; Shimada T; Fukunaga Y
    Eur J Pediatr; 2003 Jul; 162(7-8):524-525. PubMed ID: 12845529
    [No Abstract]   [Full Text] [Related]  

  • 36. Enzyme replacement therapy for mild patients with Gaucher disease.
    Zimran A; Ilan Y; Elstein D
    Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
    [No Abstract]   [Full Text] [Related]  

  • 37. Recommendations for treating patients with Gaucher disease with emerging enzyme products.
    Cox TM
    Blood Cells Mol Dis; 2010; 44(2):84-5. PubMed ID: 20022772
    [No Abstract]   [Full Text] [Related]  

  • 38. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.
    Barton NW; Brady RO; Dambrosia JM; Doppelt SH; Hill SC; Holder CA; Mankin HJ; Murray GJ; Zirzow GC; Parker RI
    J Pediatr; 1992 Feb; 120(2 Pt 1):277-80. PubMed ID: 1735829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathologic fractures may develop in Gaucher patients receiving enzyme replacement therapy.
    Sidransky E; Ginns EI; Westman JA; Ehmann WC
    Am J Hematol; 1994 Nov; 47(3):247-9. PubMed ID: 7942798
    [No Abstract]   [Full Text] [Related]  

  • 40. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease.
    Serratrice C; Swiader L; Serratrice J; Weiller PJ; Verrot D
    Eur J Intern Med; 2012 Mar; 23(2):e71-2. PubMed ID: 22284262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.